Druggable genome and precision medicine in cancer: current challenges
CA Dupont, K Riegel, M Pompaiah, H Juhl… - The FEBS …, 2021 - Wiley Online Library
The past decades have seen tremendous developments with respect to “specific”
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
Druggable genome and precision medicine in cancer: current challenges.
CA Dupont, K Riegel, M Pompaiah, H Juhl… - The FEBS …, 2021 - europepmc.org
The past decades have seen tremendous developments with respect to" specific"
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
Druggable genome and precision medicine in cancer: current challenges
CA Dupont, K Riegel, M Pompaiah… - The FEBS …, 2021 - pubmed.ncbi.nlm.nih.gov
The past decades have seen tremendous developments with respect to" specific"
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
Druggable genome and precision medicine in cancer: current challenges
CA Dupont, K Riegel, M Pompaiah, H Juhl… - The FEBS …, 2021 - cir.nii.ac.jp
抄録< jats: p> The past decades have seen tremendous developments with respect to
“specific” therapeutics that target key signaling molecules to conquer cancer. The key …
“specific” therapeutics that target key signaling molecules to conquer cancer. The key …
Druggable genome and precision medicine in cancer: current challenges
CA Dupont, K Riegel, M Pompaiah, H Juhl… - The FEBS … - openscience.ub.uni-mainz.de
The past decades have seen tremendous developments with respect to “specific”
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
[PDF][PDF] Druggable genome and precision medicine in cancer: current challenges
CA Dupont, K Riegel, M Pompaiah, H Juhl… - researchgate.net
The past decades have seen tremendous developments with respect to “specific”
therapeutics that target key signaling molecules to conquer cancer. The key advancements …
therapeutics that target key signaling molecules to conquer cancer. The key advancements …